| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6edb5285b39ab61950d1341a0eb9045f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 |
| filingDate |
2014-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa1d74bf522966cb86f9bd97a972e661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6dee72257148e3004367461d9445c61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e556d1981ad03e234b6c6925000fed8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50dba92f125f150afa8c7ccd00bdd61e |
| publicationDate |
2015-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2015120700-A |
| titleOfInvention |
Steroid composition |
| abstract |
A steroid-containing delayed release oral dosage formulation suitable for providing an individual with a therapeutically effective amount of at least one steroid. 1 to 50% w / w of one or more testosterone C2-C13 alkyl esters; 1 to 90% w / w of a hydrophilic carrier and / or 1 to 90% w / w of a lipophilic carrier; and coagulation A pharmaceutical composition for oral administration containing 1 to 50% w / w of an agent, wherein the composition is attached to a USP type 2 (paddle) device at 100 rpm and 37 ± 0.5 ° C., and 8% w / w Oral administration in which 90% or less of the testosterone C2-C13 alkyl ester is released into the aqueous medium within 30 minutes when the release test is performed in an aqueous medium that is deionized water containing v Triton X-100 Pharmaceutical composition for use. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021102562-A |
| priorityDate |
2009-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |